Sign In
Buy TNDM
$18.03
-0.570 (-3.06%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - January 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tand
New York, New York--(Newsfile Corp. - January 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tand
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
08:30pm, Wednesday, 21'st Jan 2026
NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care,
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes C
New York, New York--(Newsfile Corp. - January 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tand
NEW YORK, Jan. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes C
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
08:59pm, Friday, 16'th Jan 2026
NEW YORK, Jan. 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care,
Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 6.9% – Time to Sell?
03:14am, Sunday, 11'th Jan 2026
Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report)'s share price fell 6.9% during mid-day trading on Friday. The stock traded as low as $20.29 and last traded at $20.9450. 443,714 shares chan
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Recommendation of “Hold” from Analysts
01:40am, Sunday, 11'th Jan 2026
Shares of Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report) have received an average recommendation of "Hold" from the eighteen analysts that are covering the company, Marketbeat.com reports
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
04:05pm, Thursday, 08'th Jan 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2025 results after
Tandem Diabetes Care (NASDAQ:TNDM) Shares Cross Above 200 Day Moving Average – Here’s What Happened
03:16am, Wednesday, 07'th Jan 2026
Tandem Diabetes Care, Inc. (NASDAQ: TNDM - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $16.20 and trade
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
07:08pm, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care,
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes C
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
06:24pm, Thursday, 25'th Dec 2025
NEW YORK , Dec. 25, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes C
